Search Results

January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position

tracking biased signaling in Class B GPCRs, the membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics. 

and Clinical Pharmacology 2026 GPCR Jobs Senior Associate Scientist - Global Research Technologies Novo Nordisk Scientist I - Global Research Technologies Novo Nordisk Postdoctoral Associate Research Technologist

After working in the US and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer.

University of Copenhagen, where he has received an ERC Starting Grant, Lundbeck Foundation Fellowship, and Novo Nordisk Foundation Ascending Investigator awards.

Jacek Mokrosiński "Jacek is a Senior Scientist at Novo Nordisk specializing in molecular pharmacology Since 2021, Jacek has been working at Novo Nordisk at its research sites in the UK (Oxford) and the US